Table 2.
Percentage change in bone mineral density
| Treatment from month 0 to month 24: Treatment from month 24 to month 36: Treatment from month 36 to month 48: |
Romosozumab 210 mg QMa Placebob Romosozumab 210 mg QMc N = 19 |
Romosozumab 210 mg QMa Denosumab 60 mg Q6Mb Romosozumab 210 mg QMc N = 16 |
|---|---|---|
| Lumbar spine | ||
| Month 0 to month 24 | 15.5 (12.6, 18.4) | 16.4 (14.0, 18.7) |
| Month 24 to month 36 | − 9.1 (− 10.6, − 7.5) | 2.5 (1.0, 3.9) |
| Month 36 to month 48 | 12.4 (10.4, 14.5) | 2.3 (0.3, 4.4) |
| Month 0 to month 48 | 17.6 (13.7, 21.4) | 22.1 (17.8, 26.4) |
| Total hip | ||
| Month 0 to month 24 | 7.0 (5.3, 8.8) | 5.3 (3.0, 7.5) |
| Month 24 to month 36 | − 5.3 (− 7.3, − 3.3) | 2.0 (0.7, 3.3) |
| Month 36 to month 48 | 6.0 (4.5, 7.5) | − 0.1 (− 1.2, 0.9) |
| Month 0 to month 48 | 7.1 (5.2, 9.1) | 7.3 (4.5, 10.2) |
| Femoral neck | ||
| Month 0 to month 24 | 7.0 (4.5, 9.5) | 4.9 (3.0, 6.8) |
| Month 24 to month 36 | − 4.3 (− 6.6, − 1.9) | 1.3 (0.0, 2.7) |
| Month 36 to month 48 | 6.3 (3.3, 9.4) | 0.8 (−0.3, 2.0) |
| Month 0 to month 48 | 8.6 (5.4, 11.8) | 6.7 (3.8, 9.5) |
Data are mean % (95% CI)
CI, confidence interval; QM, monthly; Q6M, every 6 months
aTreatment group for the romosozumab double-blind period (study day 1 to month 24)
bTreatment group for the denosumab extension period (month 24 to month 36)
cRomosozumab second-course period (month 36 to month 48)